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Poly(vinyl alcohol) boosting therapeutic potential of  
p-boronophenylalanine in neutron capture therapy by 
modulating metabolism
Takahiro Nomoto1*†, Yukiya Inoue1†, Ying Yao1, Minoru Suzuki2, Kaito Kanamori1, 
Hiroyasu Takemoto1, Makoto Matsui1, Keishiro Tomoda1, Nobuhiro Nishiyama1,3*
In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most 
powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid 
transporters including LAT1. However, the therapeutic success of BPA has been sometimes compromised by its 
unfavorable efflux from cytosol due to their antiport mechanism. Here, we report that poly(vinyl alcohol) (PVA) 
can form complexes with BPA through reversible boronate esters in aqueous solution, and the complex termed 
PVA-BPA can be internalized into cancer cells through LAT1-mediated endocytosis, thereby enhancing cellular 
uptake and slowing the untoward efflux. In in vivo study, compared with clinically used fructose-BPA complexes, 
PVA-BPA exhibited efficient tumor accumulation and prolonged tumor retention with quick clearance from 
bloodstream and normal organs. Ultimately, PVA-BPA showed critically enhanced antitumor activity in BNCT. The 
facile technique proposed in this study offers an approach for drug delivery focusing on drug metabolism.
INTRODUCTION
Boron neutron capture therapy (BNCT) uses nuclear fission reaction 
between a boron atom (10B) and a low-energy thermal neutron, 
generating a high linear energy transfer (LET)  particle and a Li 
recoil nucleus that induce strong cytotoxic effect to cancer cells (1–3). 
Since the ranges of the  particle and Li nucleus are within 10 m, 
successful BNCT requires selective delivery of 10B to targeted cancer 
cells. In 1987, Mishima et al. demonstrated the first clinical success 
of BNCT on a malignant melanoma using p-boronophenylalanine 
(BPA) (Fig. 1A), and BPA has since been the most useful drug in 
clinical neutron capture therapy (4). BPA has the structure of phenyl-
alanine that can be recognized mainly by LAT1 amino acid trans-
porters overexpressed on many cancer cells, thereby permitting 
efficient cellular internalization (5, 6). In addition, fluorinated BPA 
(18F-BPA) was recently developed for companion diagnostics, and 
it has been experimentally demonstrated that 18F-BPA exhibits 
similar biodistribution to the unfluorinated BPA (7, 8) and allows 
us to quantitatively illustrate tumor accumulation of BPA and select 
patients who are likely to receive benefit from BNCT (9).
Although BPA has the above advantages, its clinical usage has 
been hampered by poor water solubility (10) and short retention time 
in tumors (11). The former poor water solubility is thought to orig-
inate from the chemical structure of BPA, as it has hydrophobic 
structure of phenylalanine and neutral charge at physiological pH, 
making intermolecular salts that are difficult to dissolve (10). While 
BPA-hydrochloride solution at low pH was used in the beginning 
of its clinical application, Yoshino and co-workers (10) found that 
sugars including fructose can form complexes with boronic acids in 
BPA and increase the water solubility. Thus, recent clinical studies 
have used fructose as a solubilizer. However, the problem of short 
retention time in tumors remains to be solved. As previously men-
tioned, BPA can quickly and efficiently accumulate within a target 
tumor, but BPA concentration gradually decreases during irradiation 
of thermal neutrons that usually requires 30 to 60 min, compromising 
the therapeutic potential of BPA. Currently, fructose-BPA is infused 
to patients even during irradiation of epi-/thermal neutrons to main-
tain high intratumoral boron concentration (12). This technique has 
successfully improved the therapeutic potential of BPA; however, it 
brings with it the possibility of human errors, such as dislodgement of 
the injection needle in the middle of the irradiation. In addition, the 
complicated settings required for infusion limits the number of treat-
ments per neutron source. Hence, suppressing efflux of intratumoral 
BPA should be key to optimizing the clinical outcome of BNCT.
One possible explanation for the short retention is the antiport 
mechanism of amino acid transporters including LAT1. When LAT1 
imports an extracellular substrate (for example, BPA) into the cytosol, 
it also exports an intracellular substrate such as glutamine (Fig. 1B). 
In a similar way, if the extracellular BPA concentration is decreased, 
intracellular BPA should be exchanged with an extracellular amino 
acid (Fig. 1C) (5). In line with this possible mechanism, a previous 
study reported that preadministration of substrates of LAT1 enhanced 
tumor accumulation of BPA (13), and another study demonstrated 
that preloading of BPA in cancer cells augmented the cellular uptake 
of 18F-BPA (14), indicating that both extracellular and intracellular 
BPA molecules should be subject to the antiport mechanism of LAT1. 
Considering these backgrounds, we hypothesized that modulation 
of subcellular localization of BPA should prevent intracellular BPA 
from untoward export by the antiport mechanism.
Here, to examine our hypothesis, we mixed poly(vinyl alcohol) 
(PVA) and BPA in aqueous solution, forming complexes via reversible 
boronate esters as illustrated in Fig. 1D. The complex formation does 
not affect the structure of phenylalanine in BPA; thus, the complex 
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is expected to be recognized by LAT1 similarly to BPA alone. How-
ever, the PVA-BPA complex is unlikely to pass the LAT1 transporter 
due to its macromolecular structure and is likely to be internalized 
into the cell through LAT1-mediated endocytosis, thereby resulting 
in localization in endo-/lysosomes (Fig. 1E). The BPA trapped in 
endo-/lysosomes may not be subject to the antiport mechanism of 
LAT1 on the cell membrane, thereby slowing untoward efflux from 
the intracellular region. Our results indicate that the alteration of 
the internalization pathway and subcellular localization could en-
hance intracellular retention of BPA in cultured cells. Even in a sub-
cutaneous tumor model, compared with clinically used fructose-BPA 
complexes, PVA-BPA exhibited augmented accumulation and pro-
longed retention within a tumor and exerted significantly enhanced 
antitumor effects upon neutron irradiation. Simple use of PVA as a 




PVA (Mn = 9500) was synthesized by saponification of poly(vinyl 
acetate) (PVAc) (Mw/Mn = 1.31) that was synthesized using reversible 
addition-fragmentation chain transfer (RAFT) polymerization as 
shown in fig. S1. The saponification rate was estimated to be ap-
proximately 99% by 1H nuclear magnetic resonance (NMR) spec-
troscopy. The characterizations of PVAc and PVA by gel permeation 
chromatography (GPC) and 1H NMR spectroscopy are shown in 
figs. S2 to S5. PVA-BPA was then constructed by simple mixing of 
PVA and BPA in aqueous solution. The formation of the complex 
was confirmed by 11B NMR analysis (fig. S6), in which the complex 
formation induced a shift and broadening of signal from 11B in BPA.
Cellular internalization pathway
To examine whether PVA-BPA is internalized into cells through 
endocytosis, we observed subcellular localization of PVA-BPA in 
cultured BxPC-3 cells expressing LAT1 transporter using confocal 
laser scanning microscopy (CLSM) (Fig. 2A). The cells were incu-
bated with clinically used fructose-BPA or Cy5-labeled PVA-BPA 
(Cy5-PVA-BPA) for 30 min, and BPA was visualized using a fluo-
rescent boronic acid sensor [5-(diethylamino)-2-((methylimino)
methyl)phenol (DAHMI)] developed by Hattori et al. (15, 16). 
Consistent with a previous study (16), fructose-BPA was detected 
in the whole cell, indicating its localization in the cytosol through 
LAT1. By contrast, PVA-BPA was localized in endo-/ lysosomes, 
which is highlighted by the white signals: the overlap of red (Cy5-
PVA), green (LysoTracker Red DND-99), and blue (BPA-DAHMI) 
signals. These results suggest that PVA-BPA was internalized 
into cells via endocytosis. Note that PVA-BPA–treated cells also 
showed localization of some BPA in the cytosol without Cy5 fluo-
rescence. The presence of BPA in the cytosol suggests that some of 
the BPA molecules dissociated from PVA-BPA complexes could be 
internalized through LAT1 transporters. In addition, sole Cy5 flu-
orescence could be observed on the cell surface in the CLSM image 
of PVA-BPA. Because DAHMI emits strong fluorescence upon 
reaction with boronic acid, complex formation of BPA with PVA 








































Fig. 1. Schematic illustration of influx and efflux of BPA. (A) Molecular structure of BPA (white-, gray-, red-, blue-, and pink-colored atoms are H, C, O, N, and B, respectively). 
(B) Cell internalization of BPA through the LAT1 transporter. LAT1 imports extracellular BPA and exports intracellular substrates including glutamine. (C) Efflux of intracellular 
BPA. When extracellular concentration of BPA decreases, intracellular BPA could be exchanged with an extracellular substrate including tyrosine. (D) Chemical structure of PVA 
and PVA-BPA. PVA-BPA formation does not involve phenylalanine structure in BPA, which is critical for recognition by LAT1. (E) Internalization pathway of PVA-BPA. PVA-BPA 
is expected to interact with LAT1, followed by internalization through endocytosis.
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endo-/lysosomal environment might cleave the boronate esters of 
PVA-BPA, and the liberated BPA may react with DAHMI, thereby 
emitting strong fluorescence.
Cellular uptake
Cellular uptake was examined by quantifying intracellular boron 
using inductively coupled plasma mass spectrometry (ICP-MS) both 
with and without an inhibitor for system L amino acid transporters, 
2-amino-2-norbornanecarboxylic acid (BCH), to evaluate the spec-
ificity of PVA-BPA to LAT1 (Fig. 2B). In the absence of BCH, PVA-BPA 
exhibited 2.9 times higher cellular uptake compared with fructose- 
BPA. It is noteworthy that addition of BCH significantly reduced the 
cellular uptake of both fructose-BPA and PVA-BPA, indicating that 
PVA-BPA can be recognized by system l amino acid transporters 
including LAT1. These results suggest that PVA-BPA might be 
internalized into cells via LAT1-mediated endocytosis, which may 
facilitate the cellular internalization of BPA.
Next, intracellular retention was investigated to elucidate the 
effect of alteration of subcellular localization on the metabolism of 
BPA. The cells were allowed to take up the samples for 3 hours and 
were subsequently incubated in the fresh medium without BPA. As 
shown in Fig. 2C, fructose-BPA critically decreased the intracellular 
boron amount, which is in line with a previous study reporting that 
intracellular BPA was exchanged with extracellular amino acids (5). 
PVA-BPA also exhibited a lower amount of intracellular boron after 
the additional incubation; however, compared with fructose-BPA, 
PVA-BPA exhibited 3.6 times higher intracellular boron concentra-
tion. Given that the intracellular boron concentration of PVA-BPA 
was 2.9 times higher than that of fructose-BPA before the additional 
incubation, the efflux of PVA-BPA should be more moderate than 
that of fructose-PVA. The efflux of boron observed in PVA-BPA–
treated cells might be caused by several mechanisms. First, the 
exchange of BPA in the cytosol with the extracellular amino acids 
should contribute to the efflux as observed in fructose-BPA–treated 
cells, as CLSM observation indicated that some of the BPA not 
involved in the PVA-BPA complex formation was localized in the 
cytosol. The second possible mechanism involves the antiport activity 
of LAT1 on endosomal membranes. BPA in the endo-/lysosomes 
may be transferred into the cytosol through LAT1, leading to the 
efflux by exchange transport on the cell membrane. However, these 
steps are expected to slow the untoward efflux of intracellular BPA. 
The third possibility is exocytosis, because LAT1 involved in the 
endocytosis might be recycled to the cell membrane, leading to the 
export of PVA-BPA outside the cell. The fourth possibility is degra-
dation of BPA. BPA in the cell might be metabolized into boric 
acids, which may then diffuse to the extracellular region (17). Despite 
the efflux of intracellular BPA in PVA-BPA–treated cells, the final 
intracellular boron concentration was maintained at a higher level 
compared with fructose-BPA. To summarize, PVA-BPA was inter-


















































Fig. 2. Cellular uptake and subcellular localization. (A) Confocal laser scanning microscopic images of BxPC-3 cells incubated with fructose-BPA and Cy5-labeled 
PVA-BPA. BPA and endo-/lysosomes were labeled using DAHMI and LysoTracker Red DND-99, respectively. Control cells were treated with DAHMI and LysoTracker 
Red DND-99. BPA (DAHMI), Cy5-labeled PVA, and endo-/lysosomes (LysoTracker Red DND-99) are shown in blue, red, and green, respectively. White arrows indicate 
representative colocalization of DAHMI, Cy5, and LysoTracker Red DND-99. (B) Cellular uptake of BPA. BxPC-3 cells were incubated with BPA for 3 hours without/with 
system L inhibitor (BCH). The results are expressed as means ± SD (n = 3). *P < 0.05 and **P < 0.001 (Neuman-Keuls test). (C) Intracellular retention of BPA. The cells were 
incubated with BPA for 3 hours without/with additional incubation in fresh medium without BPA. The results without the additional incubation are the same with those 
shown in (B). The results are expressed as means ± SD (n = 3).
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localization of BPA in endo-/lysosomes slowed the efflux of intra-
cellular BPA.
Biodistribution
To examine the potential of PVA-BPA for in vivo application, we 
first evaluated tumor accumulation. Fructose-BPA or PVA-BPA 
was intravenously injected to a BALB/c nude mouse bearing a sub-
cutaneous BxPC-3 tumor, and the amount of intratumoral boron 
was quantified using ICP-MS (Fig. 3A). Fructose-BPA exhibited 
high tumor accumulation at 1 and 3 hours after injection, reaching 
3.9% dose/g tumor. However, the tumor accumulation level gradually 
decreased with time, showing 1.2% dose/g tumor at 6 hours after 
injection. This decrease should be due to the untoward efflux of 
intracellular BPA. By contrast, PVA-BPA revealed significantly higher 
accumulation and longer retention in the tumor, achieving 6.4, 9.0, 
and 6.8% dose/g tumor 1, 3, and 6 hours after injection, respectively. 
Similar tumor accumulation was also observed in a subcutaneous 
CT26 tumor model in a BALB/c mouse (Fig. 3B). Fructose-BPA 
attained high tumor accumulation at 6.6% dose/g tumor 1 hour 
after injection, and the level decreased to 2.2% dose/g tumor within 
6 hours. Meanwhile, PVA-BPA maintained a high amount of intra-
tumoral boron (>6.9% dose/g tumor) for 6 hours. It should be noted 
that the efficient accumulation and the prolonged retention of PVA-
BPA within the tumor cannot be explained by the enhanced perme-
ability and retention effect (EPR effect) (18). As shown in Fig. 3 (C to 
E), PVA-BPA could be excreted from the kidney similarly to fructose- 
BPA. Because the molecular weight of PVA should be subject to 
glomerular filtration (19), PVA-BPA was quickly cleared from blood 
circulation and normal organs. PVA-BPA eventually exhibited the 
high boron concentration ratios of tumor to blood (T/B ratios) com-
parable to those of fructose-BPA (fig. S7). Considering that the EPR 
effect is caused by augmented permeability of tumor vasculature and 
Fig. 3. Biodistribution and intratumoral distribution. (A) Tumor accumulation within a subcutaneous hypovascular BxPC-3 tumor in a BALB/c nude mouse. The 
results are expressed as means ± SD (n = 4). *P < 0.01 and **P < 0.001 (Tukey post hoc test). (B) Tumor accumulation within a subcutaneous hypervascular CT26 tumor 
in a BALB/c mouse. The results are expressed as means ± SD (n = 4). **P < 0.001 (Tukey post hoc test). (C and D) Distribution to normal organs of (C) PVA-BPA and (D) 
fructose-BPA. The results are expressed as means ± SD (n = 4). (E) Distribution to normal organs 24 hours after administration. The results are expressed as means ± SD 
(n = 3). (F and G) Intratumoral distribution of Cy5-labeled PVA-BPA in (F) a BxPC-3 tumor model and (G) a CT26 tumor model. Nuclei and blood vessels were labeled 
with intravenously injected Hoechst 33342– and DyLight 488–conjugated tomato lectin, respectively.
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is generally observed with drugs exhibiting prolonged blood retention 
to increase opportunities to extravasate from vasculature into tumor 
tissue, the tumor accumulation and intratumoral retention of PVA-
BPA should be achieved by the active targeting of LAT1 and subse-
quent endocytosis delaying the efflux from the target cells as observed 
in the in vitro study (Fig. 2). This explanation for the active targeting 
can be supported by the augmented accumulation within the pancreas 
(Fig. 3C) because the murine pancreas expresses LAT1 (20), while 
LAT1 expression in the human pancreas was reported to be unde-
tectable (21). To get more insight about the tumor accumulation, 
we prepared a complex of PVA and 19F-BPA (PVA-19F-BPA) and 
evaluated its tumor accumulation (fig. S8). PVA-19F-BPA also ex-
hibited prolonged intratumoral retention compared with fructose-
19F-BPA. These results strongly suggest that complex formation with 
PVA can improve tumor accumulation and retention of BPA and 
its derivatives.
Intratumoral distribution
Since homogeneous distribution of boron is critical for successful 
treatment, we assessed intratumoral distribution of PVA-BPA. Cy5-
PVA-BPA was injected to the BxPC-3 and CT26 tumor models 
through the tail vein, and nuclei and blood vessels were labeled with 
intravenously injected Hoechst 33342– and DyLight 488–conjugated 
tomato lectin, respectively. The tumor was observed using CLSM 
3 hours after the injection of Cy5-PVA-BPA (Fig. 3, F and G). Hoechst 
33342, which was used for nucleus staining, could not efficiently reach 
the deep part (the region away from the blood vessels), and its strong 
fluorescence was observed near the blood vessels. It is reported that 
membrane-permeant Hoechst 33342 shows low interstitial penetra-
tion, possibly because cellular uptake is faster than diffusion in a tumor 
(22). By contrast, Cy5-PVA-BPA exhibited accumulation even in the 
deep part where Hoechst 33342 could not be delivered in both BxPC-3 
and CT26 tumors. Particularly in the hypervascular CT26 tumor, Cy5-
PVA-BPA nearly homogeneously distributed, which is a prerequisite 
for the complete treatment by BNCT. On the other hand, in the hypo-
vascular BxPC-3 tumor having rich stroma, strong Cy5 fluorescence 
was observed near the blood vessels, which is consistent with a previ-
ous study reporting that the stroma should disturb drug penetration 
(23). However, as previously mentioned, considerable accumulation 
of Cy5-PVA-BPA could also be observed within the deep part of the 
tumor. Thus, PVA-BPA is expected to have the potential to deliver a 
strong therapeutic effect even in the hypovascular tumor model.
Neutron capture therapy using PVA-BPA
The therapeutic potential of PVA-BPA was examined using a sub-
cutaneous BxPC-3 tumor model in a mouse. We intravenously in-
jected fructose-BPA or PVA-BPA to the mouse (10 mg BPA per mouse) 
and irradiated epi-/thermal neutrons to the tumor for 50 min 3 hours 
after injection (Fig. 4). Both fructose-BPA and PVA-BPA appreciably 
suppressed tumor growth, and PVA-BPA showed significantly higher 
antitumor activity (Fig. 4A). It is worthwhile to note that some of 
the fructose-BPA–treated tumors exhibited obvious regrowth (mouse1 
to mouse4 in Fig. 4B), while PVA-BPA suppressed tumor growth for 
a longer period of time than fructose-BPA (Fig. 4C). This enhanced 
antitumor activity of PVA-BPA is consistent with the observed aug-
mented accumulation and prolonged retention in the tumor (Fig. 3A), 
as well as the efficient intratumoral penetration (Fig. 3F).
We also evaluated antitumor activity in a subcutaneous CT26 
tumor model (Fig. 5). In a similar way to the aforementioned experi-
ment, fructose-BPA or PVA-BPA was intravenously injected to the 
mouse, and the tumor was irradiated with epi-/thermal neutrons for 
50 min 3 or 6 hours after injection. As shown in Fig. 5A, without neu-
tron irradiation, neither fructose-BPA nor PVA-BPA induced antitumor 
activity; however, with the irradiation, they accomplished significant 
suppression without apparent side effect (Fig. 5C). Similar to the 
study in the BxPC-3 tumor model (Fig. 4), PVA-BPA exhibited a sig-
nificantly higher antitumor effect (Fig. 5B). The strong antitumor effect 
of PVA-BPA with 3-hour interval was also confirmed by histological 
analysis of the tumor after treatment (Fig. 5, D and E). While the 
fructose-BPA–treated tumor still had living tumor cells as characterized 
with large nuclei, the PVA-BPA–treated tumor revealed shrinkage of 
nuclei, indicating the death of tumor cells. These results suggest the 
importance of intratumoral retention of BPA in NCT.
DISCUSSION
In this study, to control metabolism of BPA by modulating its sub-
cellular localization, we used PVA for complex formation with BPA 
A B C
Fig. 4. Antitumor effect in a subcutaneous hypovascular BxPC-3 tumor model. (A) Tumor growth curves. The indicated samples were intravenously injected, and the 
tumors were irradiated with epi-/thermal neutrons 3 hours after injection on day 0. The results are expressed as means ± SD (n = 8 for control; n = 6 for fructose-BPA and 
PVA-BPA). *P < 0.05 (one-way Student’s t test). (B and C) Individual tumor growth treated with (B) fructose-BPA and (C) PVA-BPA.
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because of the extremely high dose of BPA compared with the other 
therapeutic drugs. In clinical BNCT, intratumoral boron concen-
tration should be more than 25 parts per million to attain effective 
therapeutic outcome. To achieve this high intratumoral boron con-
centration, BPA is injected to patients at a dose of 500 mg/kg. Thus, 
the polymer that forms a complex with BPA should be also injected 
at a likewise high dose and should be considerably biocompatible. 
In addition, to minimize the dose of the polymer, it should have a 
simple chemical structure. In this regard, PVA has been widely studied 
as a biocompatible polymer (24, 25), and it also has the simplest 
chemical structure necessary to form the boronate ester. These char-
acteristics made PVA suitable for the purpose of this study.
Clinical BNCT prefers high T/B ratios or boron concentration 
ratios of tumor to normal organs (T/N ratios) to avoid untoward 
radiation damage to normal organs. Generally, drug delivery systems 
showing long circulation in the bloodstream have difficulty in achieving 
the high T/B ratio. Hence, we used PVA with Mn < 10,000 to induce 
quick clearance of BPA from the body. As shown in Fig. 3C and 
fig. S7, PVA-BPA was quickly cleared from the body, and the T/N 
and T/B ratios were comparable to those of fructose-BPA. Likely owing 
to the quick clearance and biocompatibility of PVA, PVA-BPA did 
not show apparent severe toxicity. Despite the quick clearance from 
the blood, PVA-BPA accomplished efficient tumor accumulation as 
we conjugated BPA molecules with PVA through boronate esters to 
expose phenylalanine structures of BPA molecules to target LAT1. 
We recently reported that polymers having multiple glutamines have 
a strong affinity to dense ASCT2 transporters (glutamine transporters) 
that are overexpressed on tumor cells through the multivalent effect 
and can be efficiently taken up by the cells through ASCT2-mediated 
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Fig. 5. Antitumor effect in a subcutaneous hypervascular CT26 tumor model. (A and B) Tumor growth curves. The indicated samples were intravenously injected, 
and the tumors were irradiated with epi-/thermal neutrons 3 or 6 hours after injection on day 1. The results are expressed as means ± SD. *P < 0.05, **P < 0.00001, and 
***P < 0.00000001 (Bonferroni method) in (A). N.S., not significant. **P < 0.0001 and ***P < 0.000001 (Bonferroni method) in (B). (C) Body weight. The results are expressed 
as means ± SD. (D and E) Histology (hematoxylin and eosin) of tumors treated by BNCT with (D) fructose-BPA and (E) PVA-BPA (3-hour interval). The tumors were collected 
25 days after the treatment. The dashed rectangle in (D) indicates a representative damaged region characterized by shrinkage of nuclei.
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transporter-targeted delivery of nanoparticles and their internalization 
through transporter-mediated endocytosis (27). The cellular uptake 
mechanism of PVA-BPA may be similar to these systems because 
our PVA-BPA could be internalized into tumor cells through LAT1- 
mediated endocytosis, thereby enhancing cellular uptake (Fig. 2, 
A and B). Note that the multivalent effect of PVA-BPA was not 
clarified in this study. However, even if PVA-BPA could not induce 
multivalent interaction with LAT1, PVA-BPA should still have the 
potential to induce LAT1-mediated endocytosis, as it was previously 
reported that introduction of a phenylalanine structure to a polymer 
could facilitate the interaction of the polymer with LAT1, resulting 
in LAT1-mediated endocytosis (28). According to previous studies 
(27, 28), physicochemical properties including hydrophilicity of 
the ligand (transporter substrate)–conjugated polymer and ligand 
density may also be the critical parameters determining the inter-
action with the targeted transporter and subsequent cellular uptake. 
Elucidation of these parameters may be important for the transla-
tion of PVA-BPA to a clinical setting, and we are now developing a 
series of polymer-BPA conjugates having various physicochemical 
properties. These topics will be discussed in our future work.
Through the LAT1-mediated endocytosis, PVA-BPA was local-
ized in the endo-/lysosomes and accomplished prolonged retention 
in the tumor (Figs. 2C and 3, A and B), thereby enhancing the BNCT 
effect (Figs. 4 and 5). However, the in vitro analysis (Fig. 2C) indicated 
obvious decrease in intracellular BPA, which appears to be incon-
sistent with the drastically prolonged tumor retention observed in 
the in vivo study (Fig. 3, A and B). This discrepancy between in vitro 
and in vivo may be explained by the extreme condition of the in vitro 
experiment, in which BPA was completely removed during the 
additional incubation, allowing the cells to efflux BPA. In actual 
in vivo studies, the extracellular region contains BPA, which should 
also be taken up by tumor cells and compensate for the exported 
BPA. Also, the slightly prolonged retention in the blood (Fig. 3C) 
might contribute to the intratumoral retention of PVA-BPA. PVA-
BPA in the bloodstream might supply BPA to the tumor even during 
irradiation of thermal neutrons, leading to the enhanced BNCT 
effect (Figs. 4 and 5). Nevertheless, we used PVA with the molecular 
weight (Mn) < 10,000, permitting the quick renal clearance. PVA-
BPA eventually exhibited the high T/B ratios comparable to fructose- 
BPA (fig. S7).
In addition to the above-described tumor retention, controlling 
intratumoral distribution of 10B is an important factor in determining 
the therapeutic outcome of BNCT, as the range of  particles and Li 
recoil nuclei is limited to 10 m. Nakamura et al. reported that lipo-
somal boron clusters enhanced tumor accumulation, but the hetero-
geneous intratumoral distribution should compromise the therapeutic 
efficacy (29). In addition, we previously reported that size of drug 
delivery systems critically affects their intratumoral distribution; 
nanoparticles with a diameter of 70 nm could not penetrate into the 
deep regions of a BxPC-3 tumor characterized by rich stroma and 
hypovascularity, while those with a diameter of 30 nm exhibited ef-
ficient penetration (23, 30). Because the molecular weight (Mn) of 
our PVA was <10,000, it is expected that PVA-BPA can efficiently 
penetrate into the deep regions. Cy5-PVA-BPA reached the deep 
part of the tumor where Hoechst 33342 could not stain the nuclei 
(Fig. 3F). Besides, the efficient penetration might be partly due to 
the extremely high dose of BPA. In the biodistribution study (Fig. 3, 
A and B), PVA-BPA exhibited >6% dose/g tumor, which corresponds 
to >2 mM of BPA in the tumor. According to the previous study (6), 
LAT1 should be saturated at this concentration. Thus, although 
PVA- BPA can be efficiently taken up by the tumor cells through 
LAT1-mediated endocytosis (Fig. 2B), there should be a considerable 
amount of PVA-BPA in the extracellular region. Such PVA-BPA may 
not stay near blood vessels but penetrate into the deep region.
Note that the high dose of BPA may also contribute to the stable 
complex formation of PVA-BPA. One may wonder about the disso-
ciation of PVA-BPA in the blood containing abundant glucose be-
cause the apparent binding constant between PVA and BPA at pH 
7.4 was 0.8 times that between glucose and BPA, which was quanti-
fied by fluorescence analysis with Alizarin red S (31). However, the 
BPA concentration in the blood should be much higher (approxi-
mately 20 mM) than the glucose concentration (roughly 5 mM) if 
all the injected BPA was mixed with the blood in the body. Most 
BPA molecules should be still conjugated to PVA immediately 
after injection. Meanwhile, it is well known that lowered pH de-
creases binding constants between boronic acids and diols. Slightly 
acidic tumorous pH may facilitate the dissociation of BPA from 
PVA-BPA. Thus, the intratumoral distribution of BPA might be dif-
ferent from the observed Cy5-fluorescent image, but the dissociated 
BPA is expected to diffuse into the deep region. Since such analysis 
would be helpful to estimate its therapeutic effect with irradiation of 
thermal neutrons and important for the clinical translation of PVA- 
BPA, we plan to analyze the distribution of the boron of PVA-BPA 
using autoradiography and may report it in the future study.
Efficient intratumoral penetration, however, does not always guar-
antee a complete cure in BNCT using BPA. The therapeutic effect of 
BPA has been compromised not only by the clearance from the tumor 
but also by quiescent tumor cells showing lower cellular uptake of 
BPA compared with other cells (32, 33). This may partly account for 
the regrowth of the fructose-BPA–treated CT26 tumors (Fig. 5, A, 
B, and D). By contrast, PVA-BPA exhibited enhanced antitumor 
activity (Figs. 4 and 5), and histological analysis indicated complete 
cure in some CT26 tumor models (Fig. 5E). It is likely that PVA-BPA 
altered the cellular uptake pathway and might increase the uptake 
efficiency even in the quiescent cells. This possibility will be further 
investigated in our future work because such analysis into boron 
distribution with simulation of radiation dose would be necessary 
for rationale prediction of the radiobiological effect of BNCT (34).
With respect to the clinical prediction of the BNCT effect, posi-
tron emission tomography (PET) using 18F-BPA is a powerful tool 
used as companion diagnostics. Because the half-life of 18F is only 
1.8 hours, it is generally difficult to conjugate or encapsulate 18F-BPA 
within nanoparticles such as liposomes and micelles that require 
many steps for manufacture. On the other hand, PVA-19F-BPA can 
be easily and promptly prepared in aqueous solution, and PVA-19F-BPA 
demonstrated enhanced tumor accumulation and retention (fig. S8). 
Thus, the concept of this study can be extended to the companion 
diagnostics using PET with 18F-BPA. PET with PVA-18F-BPA would 
clarify the biodistribution in patients, which cannot be precisely ex-
pected from experiments using animals. For example, as aforemen-
tioned, a murine pancreas expresses high level of LAT1 unlike that 
of a human (20, 21). The PET technique should overcome the dis-
crepancy of pharmacokinetics, which is caused by difference be-
tween species. These theranostic benefits provided by the simple 
preparation of PVA-BPA would permit its smooth clinical application.
Although PVA-BPA benefits from the aforementioned advantages, 
further investigation is necessary before its expansion to the clinical 
setting. First, the molecular weight of PVA should be optimized. PVA 
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(Mn = 9500) accomplished prolonged tumor retention, but increasing 
or decreasing the molecular weight may affect the therapeutic po-
tential and side effects. As a previous study described (19), the mo-
lecular weight of PVA critically affects its biodistribution. A higher 
molecular weight of PVA should lead to its longer retention in the 
blood as well as more efficient tumor accumulation via the EPR ef-
fect. However, as discussed above, long blood circulation lowers the 
T/B ratio, which is not preferable in BNCT. Thus, it is necessary to 
elucidate the optimal molecular weight of PVA-BPA that permits 
enhanced tumor accumulation and retention with quick clearance 
from the blood and normal organs. Second, possible side effects 
should be further investigated even though PVA has been clinically 
used and its excellent biocompatibility has been widely reported 
(24, 25). Since one of the most important advantages of BNCT is its 
minimal invasiveness, even minute effects on normal organs must 
not be ignored, and these issues are currently being studied further.
MATERIALS AND METHODS
Materials
BPA (10B) was purchased from Katchem spol s.r.o. (Praha, the Czech 
Republic). 19F-BPA was obtained from Fluorotech LLC (Gainesville, 
FL). Vinyl acetate (VAc), d-fructose, benzene, tetrahydrofuran (THF), 
Alizarin red S, 10% formalin neutral buffer solution, nitric acid, hy-
drochloric acid (HCl), and sodium hydroxide (NaOH) were pur-
chased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). 
The reagents for hematoxylin and eosin stain were purchased from 
Muto Pure Chemicals Co. Ltd. (Tokyo, Japan). BPA (11B), 2,2′-azobis 
(2-methylpropionitrile) (AIBN), cyanomethyl methyl(phenyl) 
carbamodithioate (CTA), BCH, penicillin-streptomycin solution, 
and trypsin-EDTA solution were purchased from Sigma-Aldrich 
(St. Louis, MO). 4-Diethylaminosalicylaldehyde and methylamine 
were purchased from Tokyo Chemical Industry Co. Ltd. (Tokyo, 
Japan). Hexane and ethyl acetate were purchased from Kanto 
Chemical Co. Inc. (Tokyo, Japan). Methanol (MeOH), dimethyl 
sulfoxide (DMSO), Dulbecco’s phosphate-buffered saline (D-PBS), 
and sodium chloride were obtained from Nacalai Tesque Inc. (Kyoto, 
Japan). LysoTracker Red DND-99 and Hoechst 33342 were purchased 
from Thermo Fisher Scientific (Waltham, MA). Cy5 NHS ester was 
obtained from Lumiprobe Corporation (Hunt Valley, MD). PD-10 
column was purchased from GE Healthcare Japan Corporation 
(Tokyo, Japan). Cell culture dishes and glass-base dishes were ob-
tained from AGC Techno Glass Co. Ltd. (Shizuoka, Japan). PTFE 
(polytetrafluoroethylene) syringe filter (0.5 m) was obtained from 
Advantec (Tokyo, Japan). Polyvinylidene difluoride syringe filter 
(0.45 m) was obtained from Merck KGaA (Darmstadt, Germany). 
DyLight 488–labeled Lycopersicon esculentum (tomato) lectin was 
purchased from Vector Laboratories (Burlingame, CA). O.C.T. com-
pound was obtained from Sakura Finetek Japan Co. Ltd. (Tokyo, 
Japan). Fetal bovine serum (FBS) was obtained from Biosera (Kansas 
City, MO). Entellan new was purchased from Merck KGaA.
Cells and animals
BxPC-3 human pancreatic adenocarcinoma cells and CT26 murine 
colon cancer cells were purchased from the American Type Culture 
Collection (Manassas, VA), and RPMI 1640 medium containing 
10% FBS and 1% penicillin-streptomycin was used as culture medium. 
Cells were cultured in a humidified atmosphere containing 5% CO2 
at 37°C. Animals were obtained from Charles River Laboratories 
Japan Inc. (Yokohama, Japan). All the animal experiments were 
approved by the Animal Care and Use Committee of Tokyo Institute 
of Technology and the Animal Care and Use Committee of Kyoto 
University. The experiments were performed in accordance with the 
Guidelines for the Care and Use of Laboratory Animals as stated by 
Tokyo Institute of Technology and the Guidelines for the Care and 
Use of Laboratory Animals as stated by Kyoto University.
Synthesis of PVAc
PVAc was synthesized using RAFT polymerization, following a pre-
vious report (35). Typically, AIBN (0.0174 mmol), CTA (0.0174 mmol), 
and VAc (34.8 mmol) were mixed in a flask under Ar atmosphere. 
After degassing by freeze-pump-thaw cycles, the mixture was stirred 
at 60°C. Following 24-hour reaction, the mixture was dialyzed against 
THF and freeze dried with benzene. PVAc was obtained as an orange 
solid. Molecular weight distribution and degree of polymerization were 
determined by GPC [column: TSKgel SuperAW3000, SuperAW4000, 
and SuperAWL-guard column (Tosoh Corporation, Yamaguchi, 
Japan); eluent: NMP (N-methyl-2-pyrrolidone) containing 50 mM 
lithium bromide; flow rate: 0.3 ml/min; detector: refractive index; 
temperature: 40°C] (fig. S2) and 1H NMR (Bruker Avance III, 400 MHz, 
Bruker BioSpin, Billerica, MA) (fig. S3).
Synthesis of PVA
PVA was obtained by saponification of PVAc. Briefly, PVAc 
(0.062 mmol) was dissolved in 30 ml of MeOH in a flask, and NaOH 
(5 equivalent to VAc units) and water were added to the solution. 
The mixture was stirred at 60°C for 24 hours and dialyzed against 
water. After filtering the obtained solution using a syringe filter 
(0.45 m), PVA was obtained as a white solid by lyophilization. The 
obtained PVA was characterized by GPC [column: Superdex 200 
Increase (GE Health Care Japan, Tokyo, Japan); eluent: buffer con-
taining 10 mM phosphate and 140 mM NaCl (pH 7.4); flow rate: 
0.75 ml/min; temperature: room temperature] (fig. S4) and 1H NMR 
(Bruker Avance III, 400 MHz) (fig. S5).
Synthesis of Cy5-PVA
To label PVA with Cy5, PVA was dissolved in DMSO, and Cy5-
NHS (1.2 equivalent to PVA) was added to the solution and stirred 
for 3 hours at room temperature. After the reaction, the solution 
was dialyzed against water, and free Cy5 was removed using PD-10 
column.
Synthesis of DAHMI
Following a previous study (15), DAHMI for detecting BPA was 
synthesized by the reaction of 4-diethylaminosalicylaldehyde and 
methylamine in methanol with reflux for 24 hours, followed by the 
concentration in vacuo and subsequent purification by flash SiO2 
column chromatography (eluent: hexane/ethyl acetate).
11B NMR analysis
Fructose-BPA solution was prepared by dissolving fructose (574 mM) 
and BPA (191 mM) in aqueous buffer solution containing 10 mM 
phosphate and 140 mM NaCl (pH 9.5). PVA-BPA solution was also 
prepared by dissolving PVA (574 mM of diol unit) and BPA (191 mM) 
in the buffer. BPA solution was prepared just by dissolving BPA in 
the buffer without solubilizer. Each sample was mixed with D2O 
(v/v = 9/1), and 11B NMR was measured using Bruker Avance III 
HD 500 (500 MHz, Bruker BioSpin).
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Quantification of apparent complex formation constant 
between PVA and BPA
Apparent complex formation constant was quantified using Alizarin 
red S following the protocol reported in a previous study (31). Fluo-
rescence of Alizarin red S–BPA complexes was measured with glucose 
or PVA at variable concentrations using a fluorophotometer (FP-8300, 
JASCO Corporation, Tokyo, Japan). The apparent complex formation 
constant was calculated with the assumption that a glucose molecule 
should form a complex with a BPA molecule, while a diol unit in 
PVA should form a boronate ester.
CLSM observation of subcellular localization
BxPC-3 cells were seeded on a glass-base dish (5 × 104 cells per dish) 
and incubated for 24 hours. After removing the medium, the cells 
were incubated in medium [D-PBS/RPMI = 1/4 (v/v)] containing 
fructose-BPA (fructose: 290 M, BPA: 110 M) or Cy5-PVA-BPA 
(diol unit in Cy5-PVA: 340 M, BPA: 110 M) for 30 min. The cells 
were then incubated in D-PBS containing 20 M DAHMI and 50 nM 
LysoTracker Red DND-99 for 30 min, followed by washing with 
D-PBS thrice. The cells in D-PBS were observed using CLSM 
(LSM710, Carl Zeiss AG, Oberkochen, Germany).
Cellular uptake
To evaluate cellular uptake, BxPC-3 cells were seeded on a dish (5 × 106 
cells per dish) and incubated for 24 hours. After removing the 
medium, the cells were incubated in the medium [D-PBS/culture 
medium = 1/4 (v/v)] containing fructose-BPA (fructose: 7.8 mM, 
BPA: 3.0 mM) or PVA-BPA (diol unit in PVA: 3.0 mM, BPA: 3.0 mM) 
with/without BCH (20 mM) for 3 hours. The cells were then washed 
with D-PBS and detached by incubation in 1 ml of trypsin/EDTA 
solution. The cell suspension was mixed with 9 ml of culture medium, 
and the cells were collected by centrifugation. After counting the 
number of cells, they were lysed in 1 ml of 70% nitric acid and ashed 
by heating the lysate at 90°C. The ashed sample was diluted with 
water, and the volume was adjusted to 10 ml, followed by filtration 
using a syringe filter (0.5 m). The amount of boron in the filtered 
samples was quantified using ICP-MS (Agilent 7900 ICP-MS, Agilent 
Technologies Inc., Santa Clara, CA).
For the assessment of intracellular boron retention, the cells were 
incubated with fructose-BPA or PVA-BPA without BCH for 3 hours 
as described above. The cells were then incubated in fresh medium 
without BPA for 30 min to allow cells to export intracellular boron, 
followed by collection with trypsin/EDTA. The subsequent proce-
dures were the same with the aforementioned protocols.
Biodistribution
A subcutaneous BxPC-3 tumor model was prepared by subcutaneous 
inoculation of BxPC-3 cells into a BALB/c nude mouse (5 × 106 cells 
per mouse). A subcutaneous CT26 tumor model was also prepared 
by subcutaneously inoculating CT26 cells into a BALB/c mouse (2 × 
105 cells per mouse). After the tumor size reached approximately 
200 mm3, fructose-BPA (molar ratio of fructose to BPA = 3, pH 9.2 to 
9.5) or PVA-BPA (molar ratio of diol unit in PVA to BPA = 3, weight 
ratio of PVA to BPA = 1.3, pH 9.2 to 9.5) was intravenously injected 
to the mouse (BPA 8 mg per mouse). The mice were euthanized 1, 
3, or 6 hours after injection, and blood was obtained from the inferior 
vena cava and heparinized, followed by collection of tumors and 
organs. The collected samples were soaked in 1 ml of 70% nitric acid 
and ashed at 90°C. The ashed samples were diluted with water, and 
the volume was adjusted to 10 ml. After filtering the samples with 
a syringe filter (0.5 m), the amount of boron in the samples was 
quantified using ICP-MS (Agilent 7900 ICP-MS).
In the evaluation of biodistribution of 19F-BPA, fructose-19F-BPA 
(molar ratio of fructose to 19F-BPA = 3.2, pH 9.5) or PVA-19F-BPA 
(molar ratio of diol unit in PVA to 19F-BPA = 3.2, weight ratio of 
PVA to 19F-BPA = 1.3, pH 9.5) was intravenously injected to the 
mouse bearing a subcutaneous CT26 tumor (19F-BPA 8 mg per 
mouse). The tumors were collected 1 or 6 hours after injection and 
processed in the same procedures with the aforementioned methods 
for the analysis using ICP-MS.
Intratumoral distribution
Tumor models were prepared using the same procedures described 
in the section on “Biodistribution.” After the tumor size reached 
approximately 200 mm3, Cy5-PVA-BPA (molar ratio of diol unit in 
Cy5-PVA to BPA = 3, weight ratio of Cy5-PVA to BPA = 1.3, pH 9.2 to 
9.5) was intravenously injected to the mouse (BPA 8 mg per mouse). 
The mouse was then injected with Hoechst 33342 (250 g per 
mouse) and DyLight 488–labeled tomato lectin (25 g per mouse) 
2.5 hours after injection of Cy5-PVA-BPA to visualize nuclei and 
blood vessels, respectively. After 30 min, the mouse was euthanized, 
and the tumor was collected and cut in half. The cut tumor was put 
on a glass-base dish, and the cross section was observed under a 
humidified atmosphere using LSM710. Three-dimensional imaging 
was constructed using the Imaris software (Bitplane AG, Zurich, 
Switzerland).
Neutron capture therapy to BxPC-3 tumor models
BxPC-3 cells (5 × 106 cells per mouse) were subcutaneously inoculated 
into the right thighs of BALB/c nude mice. The tumors were allowed 
to grow for ~2 months. The mouse was injected with fructose-BPA 
(molar ratio of fructose to BPA = 3, pH 9.2) or PVA-BPA (molar ratio 
of diol unit in PVA to BPA = 3, weight ratio of PVA to BPA = 1.3, 
pH 9.2) at a dose of 10 mg of BPA per mouse. The mice were placed 
in acrylic holders, which were secured on a 5-mm-thick thermoplastic 
plate that contained 40 weight % (wt %) of 6LiF (96% 6Li) to block 
thermal neutrons and had a circular hole in the center. The thigh 
containing the tumor was stretched over the hole, and the tumor 
was irradiated with epi-/thermal neutrons for 50 min (fluence: 9.9 × 
1011 to 4.5 × 1012 neutrons/cm2) 3 hours after the injection. The 
tumor size was measured by a caliper, and the tumor volume (V) 
was calculated using the following equation: V = ab2/2, where a and 
b are the major and minor axes, respectively.
Neutron capture therapy to CT26 tumor models
CT26 cells (2 × 105 cells per mouse) were subcutaneously inoculated 
into the right thighs of BALB/c mice. The tumors were allowed to 
grow for ~2 weeks. The mice were injected with fructose-BPA (molar 
ratio of fructose to BPA = 3, pH 9.5) or PVA-BPA (molar ratio of 
diol unit in PVA to BPA = 3, weight ratio of PVA to BPA = 1.3, pH 9.5) 
at a dose of 10 mg BPA per mouse. The mice were placed in acrylic 
holders, which were secured on a 5-mm-thick thermoplastic plate 
that contained 40 wt % of 6LiF (96% 6Li) to block thermal neutrons and 
had a circular hole in the center. The thigh containing the tumor was 
stretched over the hole, and the tumor was irradiated with epi-/thermal 
neutrons for 50 min (fluence: 1.1 × 1012 to 3.8 × 1012 neutrons/cm2) 
3 or 6 hours after the injection. The tumor size was measured by a 
caliper, and the tumor volume (V) was calculated using the following 
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equation: V = ab2/2, where a and b are the major and minor axes, 
respectively.
Histological analysis for CT26 tumors
BNCT-treated CT26 tumors were collected 25 days after the treat-
ment and soaked in formalin solution. The fixed tumor was embedded 
in O.C.T. compound and frozen. Tissue sections with 4-m thickness 
were obtained using Leica CM3050S (Leica Biosystems, Wetzlar, 
Germany) and stained with hematoxylin and eosin. The tissue 
section was embedded in Entellan new and observed using a micro-
scope (BZ-X710, Keyence Corporation, Osaka, Japan).
Statistical analysis
Statistical analysis was conducted using Student’s t test, one-way 
analysis of variance (ANOVA), and two-way ANOVA with post hoc 
analysis. The P values less than 0.05 were considered statistically 
significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/4/eaaz1722/DC1
Fig. S1. Synthetic scheme of PVAc and PVA.
Fig. S2. GPC chart of PVAc.
Fig. S3. 1H NMR spectrum of PVAc in DMSO-d6.
Fig. S4. GPC chart of PVA.
Fig. S5. 1H NMR spectrum of PVA in DMSO-d6.
Fig. S6. 11B NMR spectra of BPA, fructose-BPA, and PVA-BPA.
Fig. S7. T/B ratios in BxPC-3 and CT26 tumor models.
Fig. S8. Tumor accumulation of fructose-19F-BPA and PVA-19F-BPA in subcutaneous CT26 
tumor models.
View/request a protocol for this paper from Bio-protocol.
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